- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01125085
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT) in Patients With Multiple Brain Metastases From Solid Tumors
The aim of this Proof of Concept study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with external beam radiation, for the treatment of patients with multiple brain metastases following the promising results with this agent in previous clinical studies.
The L19SIP antibody is a fully human antibody, capable of preferential localization around tumor blood vessels while sparing normal tissues. The formation of new blood vessels is a rare event in the adult (exception made for the female reproductive cycle), but is a pathological feature in most aggressive types of cancer. The presented study follows a Phase I and a subsequent Phase I/II dose finding and efficacy study with the same agent in patients with a variety of cancers where 131I-L19SIP had shown an excellent tolerability and therapeutic benefit for some patients enrolled in the study.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aviano, Italy
- Irccs Centro Di Riferimento Oncologico (Cro) - Aviano
-
Bergamo, Italy
- Ospedali Riuniti di Bergamo
-
Firenze, Italy
- Azienda Ospedaliero UNIVERSITARIA CAREGGI DI FIRENZE
-
Macerata, Italy
- ASUR Zona Territoriale 9, Medicina Nucleare Ospedale di Macerata
-
Napoli, Italy
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli
-
Reggio Emilia, Italy
- Arcispedale Santa Maria Nuova di Reggio Emilia
-
Rozzano (mi), Italy
- Irccs Istituto Clinico Humanitas
-
San Giovanni Rotondo (FG), Italy
- Irccs Ospedale Casa Sollievo Della Sofferenza - San Giovanni Rotondo
-
-
-
-
-
London, United Kingdom
- Barts and the London NHS Trust Hospital
-
London, United Kingdom
- UCLH, Department of Cancer Medicine, London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 6.3.1 Inclusion Criteria for Dosimetric Study Part (diagnostic 131I-L19SIP or 124I-L19SIP) and therapeutic study part
- Unresectable multiple brain metastasis from histologically or cytologically confirmed solid tumors. In exceptional cases also patients with a single brain metastasis if not amenable for surgical treatment might be included.
- Males or females, age > 18 years
- Measurable disease defined as at least one metastatic brain lesion that can be accurately and serially measured by the modified RECIST criteria (version 1.1)
- Prior therapy for metastatic disease allowed
- RPA Class II
- Life expectancy of at least 12 weeks
- Serum creatinine < 1.5 x ULN
- All toxic effects of prior therapy must have resolved to ≤ Grade 1 unless otherwise specified above
- Negative serum pregnancy test (for women of child-bearing potential only) at screening
- If of childbearing potential, agreement to use highly effective contraceptive methods (e.g., established use of oral, injected or implanted hormonal methods, placement of intrauterine device or intrauterine system, use of condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization or true abstinence) beginning at the screening visit and continuing until 3 months following last treatment with study drug.
- In case of treated males (including men who have had vasectomies) who have a partner who is pregnant or of child-bearing potential, agreement to use condoms beginning at the screening visit and continuing until 3 months following last treatment with study drug.
- Patients with microhaemorrhage can be included if the microhaemorrhage does not appear to significantly contribute to symptoms caused by the particular brain lesion and if the microhaemorrhage does not appear to significantly contribute to a possible mass effect of the brain lesion in question.
Additional Inclusion Criteria for Therapeutic Study Part
- Absolute neutrophil count > 1.0 x 109/L, hemoglobin > 8.0 g/dL (packed red cell transfusions allowed), and platelets > 100 x 109/L
- Total bilirubin ≤ 30 µmol/L (or ≤ 2.0 mg/dL). For patients with liver involvement with tumor total bilirubin ≤ 45 µmol/L (or ≤ 3.0 mg/dL).
- ALT and AST ≤ 2.5 x the upper limit of normal (10 x ULN for patients with hepatic involvement with tumor
Exclusion Criteria:
- Primary ocular melanoma
- Patients with brain metastasis amenable for surgical excision or stereotactic irradiation (radiosurgery)
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated < 5 years prior to study entry
- Patients with history of whole brain irradiation
- History of HIV infection or infectious hepatitis B or C
- Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
- Inadequately controlled cardiac arrhythmias including atrial fibrillation
- Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria)
- Uncontrolled hypertension
- Ischemic peripheral vascular disease (Grade IIb-IV)
- Severe diabetic retinopathy
- Active autoimmune disease
- History of organ allograft or stem cell transplantation
- Recovery from major trauma including surgery within 4 weeks prior to administration of study treatment
- Pregnant woman
- Breast feeding female
- Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment
- Growth factors or immunomodulatory agents within 7 days of the administration of study treatment
- Patients in need of systemic treatment associated with a moderate or significant potential of hematotoxicity for rapidly progressive systemic disease during study treatment and up to 4 weeks after injection of therapeutic 131I-L19SIP.
- Hyperthyroidism or autonomous thyroid nodule
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 131I-L19SIP RIT in Combination with WBRT
131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uptake of 131I-L19SIP or 124I-L19SIP
Time Frame: 2 days
|
Selective uptake of 131I-L19SIP or 124I-L19SIP in brain lesions
|
2 days
|
Safety of combined administration of 131I-L19SIP and whole brain radiation therapy (WBRT)
Time Frame: 13 months
|
Safety will be assessed through physical examinations, vital signs, laboratory tests (including serum chemistries, hematology parameters) and the recording of adverse events.
Treatment emergent adverse events will be summarized by CTCAE version 3 (and if possible by the RTOG/EORTG scale) and worse grade for all treated patients.
Laboratory values and change in vital signs will be summarized.
|
13 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 12 months
|
12 months
|
|
Overall response
Time Frame: 12 months
|
Intracranial, extra cranial and overall response
|
12 months
|
Clinical performance index in terms of Graded Prognostic Assessment (GPA)
Time Frame: 12 months
|
GPA score will be assessed at the screening visit, during treatment and follow-up.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Secondo Lastoria, Dr, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli
- Principal Investigator: Paul Mullholand, Dr, UCLH, Department of Cancer Medicine, London (UK)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PH-L19SIPI131-01/09
- 2009-013002-13 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases From Solid Tumors
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.UnknownBone Metastasis From Solid Tumors
-
University of Alabama at BirminghamNot yet recruitingHealthy Volunteers | Recurrent Glioma | Brain Metastases From Extra-cranial Solid TumorsUnited States
-
Luye Pharma Group Ltd.RecruitingBone Metastases From Solid TumorsChina
-
Shanghai JMT-Bio Inc.CompletedBone Metastases From Solid TumorsChina
-
Bristol-Myers SquibbCompletedNeoplasms | Solid Tumors | MetastasesAustralia
-
National Cancer Institute (NCI)CompletedSolid Tumors | Brain Tumors | Brain MetastasesUnited States
-
Aposense Ltd.UnknownSolid Tumors | Brain MetastasesUnited States
-
Aposense Ltd.CompletedSolid Tumors | Brain Metastases
-
Azienda Ospedaliero-Universitaria CareggiRecruitingBrain Metastases From NSCLCItaly
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
-
Philogen S.p.A.TerminatedNon Small Cell Lung CancerItaly
-
NRG OncologyNational Cancer Institute (NCI)CompletedCognitive Impairment | Metastatic Malignant Neoplasm in the Brain | Solid NeoplasmUnited States, Canada